

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM526572


<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
Ash Access Technology, Inc.		08/30/2011	Corporation: INDIANA
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	AngioDynamics, Inc.		
<b>Street Address:</b>	14 Plaza Drive		
<b>City:</b>	Latham		
<b>State/Country:</b>	NEW YORK		
<b>Postal Code:</b>	12110		
<b>Entity Type:</b>	Corporation: DELAWARE		
<b>PROPERTY NUMBERS Total: 1</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	3541404	CENTROS	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	5187951401		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Email:</b>	uspto@angiodynamics.com		
<b>Correspondent Name:</b>	Peter J. Flora, Esq.		
<b>Address Line 1:</b>	14 Plaza Drive		
<b>Address Line 4:</b>	Latham, NEW YORK 12110		
<b>NAME OF SUBMITTER:</b>	Peter J. Flora		
<b>SIGNATURE:</b>	/Peter J. Flora/		
<b>DATE SIGNED:</b>	06/05/2019		
<b>Total Attachments: 6</b>			
source=Ash Access_Termination and Assignment Agreement Executed 8-30-2011_redacted (003)#page1.tif			
source=Ash Access_Termination and Assignment Agreement Executed 8-30-2011_redacted (003)#page2.tif			
source=Ash Access_Termination and Assignment Agreement Executed 8-30-2011_redacted (003)#page3.tif			
source=Ash Access_Termination and Assignment Agreement Executed 8-30-2011_redacted (003)#page4.tif			
source=Ash Access_Termination and Assignment Agreement Executed 8-30-2011_redacted (003)#page5.tif			
source=Ash Access_Termination and Assignment Agreement Executed 8-30-2011_redacted (003)#page6.tif			

OP \$40.00 3541404

**TERMINATION AND ASSIGNMENT AGREEMENT**

THIS TERMINATION AND ASSIGNMENT AGREEMENT (this "Agreement"), by and among Ash Access Technology, Inc., AAT Catheter Technologies, LLC (together "Ash") and AngioDynamics, Inc. ("Angio"), is dated August 30, 2011 (the "Effective Date"). The parties to this Agreement are sometimes referred to herein collectively as "Parties," or individually as a "Party." Capitalized terms used herein but not otherwise defined shall have the meaning ascribed to them in that certain Distribution, Manufacturing and Purchase Option Agreement dated as of August 13, 2007 between Ash and Angio as modified by letter agreements dated September 1, 2009 and September 18, 2009 (the "Distribution Agreement").

WHEREAS, Ash and Angio are parties to the Distribution Agreement, pursuant to which, among other things, Ash granted Angio certain rights pertaining to the development, manufacturing and distribution of the Ash Advance and the Ash SureFlow devices (the "Devices"); and



THEREFORE, in consideration of the mutual promises set out in this Agreement, which includes the recitals above, the Parties hereby agree as follows:


1. Payment. Upon execution of this Agreement and completion of the items described in Section 2 below, Ash shall pay to Angio in accordance with wire instructions provided to Ash by Angio for the License Fee.



3. Assignment and Indemnity.

(a) Angio shall and hereby does irrevocably sell, grant, convey and assign to Ash, and its successors and assigns, all of Angio's worldwide right, title and interest in and to any and all Ash

Assets which it currently owns or may own in the future, including without limitation the right to sue for past infringement, misappropriation or other violation thereof, and all claims, causes of action and other rights of recovery, set off or recoupment of any kind against any party arising out of or relating to such Ash Assets. Ash may transfer and assign to any party the Ash Assets and any and all rights it may receive from Angio hereunder. To the extent Angio has possession of any of the Ash Assets, Angio will deliver such Ash Assets to Ash as soon as practical after the date of this Agreement, and before the payment of Section 1 is made by Ash. Angio hereby waives any claim that it may have to ownership of any of the Ash Assets, and represents and warrants that it has returned to Ash any copies of any drawings, schematics, designs or other materials related to the Ash Assets that it may have held in its possession.




(c) For the purposes of this Agreement, "Ash Assets" means (a) any and all Ash Advance, Ash SureFlow, Ash Improvements, Angio Improvements, Improvements, Ash Advance Know-How, Ash SureFlow Know-How (as such terms are defined in the Distribution Agreement), rights, know-how, technology, and Trademark "Centros ®"(collectively, the "Device Assets"), (b) any and all worldwide regulatory documentation and submissions with associated approval documentation, including without limitation, FDA 510(k) registrations, pre-market notifications, approvals, clearances, applications, extensions, renewals, and CE dossiers and registrations related to the Device Assets; (c) all approvals, permits, licenses, orders, registrations, certificates, variances, and similar rights obtained from governments and governmental agencies within the United States and foreign jurisdictions related to the Device Assets; (d) books, records, ledgers, files, documents, correspondence, lists, plans, drawings, and specifications (including all manufacturing drawings and specifications) related to the Device Assets, including without limitation all regulatory filings and filing histories; (e) all studies, reports, training materials, videos and other printed, electronic or written materials related exclusively to the Device Assets; (f) any customer, vendor and supplier lists related to the Device Assets, order histories and contact information of such customers, complaint files, and all other similar information related to the Device Assets; (g) a letter of introduction from Angio for Ash to each customer who purchased an Ash Advance or Ash SureFlow Device in form and substance reasonably satisfactory to Ash, to assist Ash in marketing the Devices to such party; (h) any manufacturing equipment, tooling, molds and other tangible personal property related solely to the Device Assets, a schedule of which is set forth on Exhibit A hereto; and (i) all inventory of Ash Advance or Ash SureFlow Devices, however packaged and under whatever trademarks or trade names, which inventory may be sold by Ash in the normal course of business following the date hereof. Notwithstanding anything contained in this Agreement or the Distribution Agreement to the contrary, Ash Assets shall not include U.S. Patent Application No. US 2010/0191165A1, published July 29, 2010, or any patent that issues from such application, or any continuations, divisional, foreign counterparts, reissues or re-examinations of any such patents or application.




(d) The foregoing assignment includes any and all right, title, and interest now in force and effect that Angio has, may have, or claims to have in any portion of the Ash Assets in the United States and all foreign countries, including but not limited to: (a) any and all trade secrets, technologies, proprietary information, know-how, code, programs, processes, concepts, methods, routines, formulas, algorithms, designs, specifications, architectures, or inventions embodied therein; (b)

*J. RB-J*


any and all copyrights, trademarks, service marks, patents, and patent rights with respect thereto, together with and any and all modifications, renewals, and extensions thereof, and any and all existing or future applications therefor; (c) any and all documents, records, reports, manuals, drawings, schematics, notes, flow charts, memoranda, printouts, graphs, writings of any kind or nature, tapes, discs, media, films, and other magnetic, computerized, electronic, visual, or audio recordings of any kind or nature containing, describing, or embodying the Ash Assets, in whole or in part, whether originals or copies (collectively, the "Intellectual Property Rights," with respect to the intangible rights related to such intellectual property, and the "Intellectual Property Materials," with respect to the tangible embodiment of such intellectual property).




*A. RBS*



*S. RB*




12. Entire Agreement. This Agreement and the agreements to be executed in connection herewith comprise the entire agreement among the Parties with respect to the subject matter hereof. This Agreement supersedes any contemporaneous or prior agreements or understandings with respect to the subject matter hereof. No representation, statement or condition related to the subject matter hereof not contained in this Agreement has any force or effect.



IN WITNESS OF THE FOREGOING, the parties have signed this Agreement as of the 30th day of August, 2011.


ANGIO:

AngioDynamics, Inc.,  
a Delaware corporation


By:   
Name: D. Joseph Gersuk  
Title: Executive Vice President and CFO

ASH:

Ash Access Technology, Inc.,  
an Indiana corporation

By:   
Name: Robert B. Truitt  
Title: President and CEO

AAT Catheter Technologies, LLC  
an Indiana limited liability company

By:   
Name: Robert B. Truitt  
Title: Manager